

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: YAYON11

In re Application of:	)	Conf. No.: 6136
Avner YAYON	)	
	)	
IA No: PCT/IL04/00529	)	Art Unit:
	)	Examiner:
IA Filed: June 17, 2004	)	Washington, D.C.
Appln. No.: 10/561,396	)	
	)	
For: TREATMENT OF T CELL	)	March 12, 2007
MEDIATED DISEASES BY...	)	

**INFORMATION DISCLOSURE STATEMENT [IDS]**

Honorable Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building, Mail Stop Amendment  
401 Dulany Street  
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[X] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below:


[X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By:

  
\_\_\_\_\_  
Sheridan Neimark  
Registration No. 20,520

SN:dac  
624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 2

**Complete if Known**

Application Number	10/561,396
Filing Date	June 17, 2004
First Named Inventor	Avner YAYON
Group Art Unit	
Examiner Name	
Attorney Docket Number	YAYON11

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AA	WO 2002/102973 A3	12-27-2002	Prochon Biotech Ltd.		
	AB	WO 03/023004 A2	03-20-2003	ISIS Pharmaceuticals, Inc.		

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/561,396
Filing Date	June 17, 2004
First Named Inventor	Avner YAYON
Group Art Unit	
Examiner Name	
Attorney Docket Number	YAYON11

Sheet 2

of 2

**NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AC	BAECKLUND, E. et al., "Lymphoma Subtypes in patients with Rheumatoid Arthritis"; Arthritis & Rheumatism; Vol. 48, No. 6, June 2003, pp. 1543-1550	
	AD	SIMON, J.A., "Biologic therapy in rheumatoid arthritis"; Rev Invest Clin; Vol. 53, No. 5, 2001, pp. 452-459	
	AE	NEPOM, G.T. et al., "Therapy of autoimmune diseases: clinical trials and new biologics"; Therapy: clinical trials; 2002, Vol. 14, pp. 812-815	
	AF	SMOLEN, J.S. et al., "Therapeutic Strategies for Rheumatoid Arthritis"; Nature Reviews; Vol. 2, June 2003, pp. 473-488	
	AG	PALEOLOG, E.M., "Angiogenesis in rheumatoid arthritis"; Arthritis Res; 2002, Vol. 4, pp. S81-S90	
	AH	MANABE, N. et al., "Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients"; Rheumatology; 1999, Vol. 38, pp. 714-720	
	AI	PATERSON, J.L. et al., "Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma"; British Journal of Haematology, Vol. 124, pp. 595-603	
	AJ	GRAND, EK et al., "Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD1730074"; Leukemia, 2004, Vol. 18, pp. 962-966	
	AK	GREGERSEN, J.W. et al., "Humanized animal models for autoimmune diseases"; Tissue Antigens, 2004, Vol. 63, pp. 383-394	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.